Polyangiitis overlap syndrome: a rare clinical entity

Rheumatol Int. 2023 Mar;43(3):537-543. doi: 10.1007/s00296-023-05281-x. Epub 2023 Jan 31.

Abstract

Polyangiitis overlap syndrome is a rare clinical entity comprising patients with overlapping features of more than one vasculitis, usually eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA). Few cases of polyangiitis overlap syndrome have been described in the literature, mostly associated with c-ANCA, anti-proteinase (PR)-3 positivity, a protean clinical picture characterized by vasculitis, eosinophilia and eosinophilic infiltrates in tissues and a favorable response to steroids and immunosuppressant treatments. Herein, we present a case of a 66-year-old woman with nasal obstruction, external nose deformity, sensorineural hearing loss, peripheral blood eosinophilia, high titer anti-PR3 antibodies and lung involvement. Nasal septum biopsies showed inflammatory infiltrate with eosinophilic component; histopathology of the lung demonstrated necrotizing granulomas associated with inflammatory infiltrate composed of numerous neutrophils and some eosinophils. The patient was diagnosed with polyangiitis overlap syndrome and successfully treated with cyclophosphamide. Recognizing this entity is fundamental given the distinct clinical phenotype and outcomes to therapy in the complex scenario of ANCA-associated vasculitides.

Keywords: ANCA; Anti-PR3; EGPA; Eosinophilia; Eosinophilic granulomatosis with polyangiitis; Granulomatosis with polyangiitis; Vasculitis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / complications
  • Antibodies, Antineutrophil Cytoplasmic
  • Churg-Strauss Syndrome* / diagnosis
  • Cyclophosphamide / therapeutic use
  • Eosinophilia* / complications
  • Granulomatosis with Polyangiitis* / diagnosis
  • Humans
  • Myeloblastin

Substances

  • Cyclophosphamide
  • Myeloblastin
  • Antibodies, Antineutrophil Cytoplasmic